R & D Pipeline
program
target
indication
moa
development stage
CT3001
TMER1-i
Small molecule
GPR35
a.k.a.
Kynurenic Acid Receptor
IO, first-in-class
GPR35+ IDO1+ Tumors:
Colon, Pdac, Gastric, NSCLC
Hippo-YAP regulator
Block IDO-mediated tumor immune escape
Block tumor growth
CT3021
TMER2-i
Small molecule
Adenosine Receptors
A2a, A2b, A1
IO, Best-in-class
A1+ CD73+ Tumors
Highly potent triple antagonist
(Ki = 0.37 nM [A2a], 1.76 nM [A2b], 1.26 nM [A1]
Full antagonism in high adenosine TME
TMER3-i
Small molecule
Undisclosed
IO, first-in-class
Solid Tumors
Hippo-YAP regulator
Block tumor immune escape
Block tumor growth
Candidate Nomination
TMER4-i
Small molecule
Undisclosed
IO, first-in-class
Solid Tumors
Hippo-YAP regulator
Block tumor growth
“Hit” to “Lead”
PD1/PD-L1 Blocker
Small molecule
IO
mono/combo with other TMER-i
“Hit” to “Lead”